PRJNA664887
Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases
Remdesivir is a broad-spectrum antiviral nucleotide prodrug that has been clinically evaluated in Ebola virus patients and recently received Emergency Use Authorization for treatment of coronavirus disease 2019. This study seeks to determine molecular markers that identify the mechanism of action of remdesivir against Ebola virus.